Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05142722 · ClinicalTrials.gov registry record · Phase 3
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
A Phase 3 study, sponsored by NewAmsterdam Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,530
- Enrollment target
NCT05142722: Completed Phase 3 study, sponsored by NewAmsterdam Pharma.
NCT05142722 is a Phase 3 study that has completed, run by NewAmsterdam Pharma. The registered enrollment target is 2,530 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (228% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05142722, a Phase 3 study, has completed, sponsored by NewAmsterdam Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,530 participants
- Enrollment target
Study Summary
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy
Primary Outcome
LS mean percent change from baseline to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[PUC\]. LDL-C level was measured by preparative ultracentrifugation (PUC).
Interventions
- DRUG Placebo
- DRUG Obicetrapib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,530 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2024-09-26 |
| Phase | Phase 3 |
What the finished NCT05142722 record still lists
NCT05142722 is an interventional study that assigns participants to a tested intervention. Its 2,530 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (228% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05142722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05142722 about?
NCT05142722 is a clinical study titled "Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies". This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-loweri...
What is the current status of trial NCT05142722?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,530 participants. The study started on 2021-12-15. Estimated completion is 2024-09-26.
What interventions are being tested in trial NCT05142722?
The interventions under investigation include: Placebo (DRUG), Obicetrapib (DRUG).
Who is sponsoring clinical trial NCT05142722?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05142722's enrollment target sits among peer trials
2,530 87th of 2000 higher than 1,914 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- NCT04142177 · 2,529 participants · NA
Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response
- NCT05931276 · 2,540 participants · Phase 3
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI